Amgen Inc. (NASDAQ:AMGN) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now.
A pharmacist filling a prescription for a complex drug developed by the company.
Amgen Inc. (NASDAQ:AMGN) is on the hunt for its next breakthrough drug— a common pursuit among pharmaceutical companies looking to stay ahead of rivals, especially as biosimilar competition grows. The company boasts a robust pipeline, with dozens of ongoing programs that could result in future drug approvals and expanded uses for existing treatments. Thanks to its strong track record of innovation, Amgen has performed well for years, and that momentum is expected to continue.
Amgen Inc. (NASDAQ:AMGN) also reported strong earnings in the first quarter of 2025. The company posted revenue of $8.15 billion, marking a 9.4% increase year-over-year. It benefited from strong global demand for its products. Management voiced optimism about its long-term growth prospects, supported by the success of recent product launches and encouraging Phase 3 trial outcomes for multiple treatments.
Amgen Inc. (NASDAQ:AMGN)’s cash flow makes it one of the most reliable dividend stocks. The company generated $1.0 billion in free cash flow during the quarter, doubling the figure from the same period a year earlier. Operating cash flow rose to $1.4 billion from $0.7 billion in the prior year. The company also returned $1.3 billion to shareholders in the form of dividends.
Amgen Inc. (NASDAQ:AMGN) offers a quarterly dividend of $2.38 per share and has a dividend yield of 3.11%, as of July 26. The company has raised its dividends every year since 2011, which places it among the best dogs of the Dow.
While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: Top 10 Safest Dividend Stocks in the UK and Dividend Champions vs Aristocrats: 12 Under-the-Radar Stocks to Buy
Disclosure: None.